Presenter: Sherly Mosessian, Ph.D
SOFIE Chief Scientific Officer
Dr. Mosessian earned her bachelors degree in Biochemistry, followed by her Ph.D from UCLA Department of Molecular, Medical Pharmacology, with publications in tumor signaling, molecular imaging targets and clinical trials of Position Emission Tomography (PET) probes. In her role as the Chief Scientific Officer of SOFIE she formulates the strategic plan for scientific objectives of the organization, including leading the FAPI clinical development program.
Date: June 8, 2022
Time: 3:30pm EDT
Who should attend? PET Interpreters, Technologists, Referring Physicians, Marketers
In this webinar, Dr. Mosessian will:
- Explain what is FAP and what role it plays in oncology
- Identify key radiopharmaceuticals involved in FAP targeting
- Describe the current state of clincal development for FAP Inhibitors (FAPI)